Furthermore, Tregs in TME have been shown to express upregulated levels of immune checkpoint molecules such as CTLA-4, PD-1, TIM-3 that can further inhibit the anti-cancer immune response by inhibiting effector T cells and influencing the function of antigen-presenting cells (APCs) [19], [20]. The gene discussed is CTLA4; the disease is cancer.